Precigen’s (PGEN) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Precigen (NASDAQ:PGEN) in a research report report published on Friday,Benzinga reports. They currently have a $4.00 price objective on the biotechnology company’s stock. HC Wainwright also issued estimates for Precigen’s FY2026 earnings at $0.01 EPS, FY2027 earnings at $0.22 EPS and FY2028 earnings at $0.39 EPS.

A number of other research analysts have also commented on the company. JMP Securities decreased their price objective on Precigen from $14.00 to $7.00 and set a “market outperform” rating on the stock in a report on Thursday, August 15th. StockNews.com raised Precigen to a “sell” rating in a report on Thursday, August 1st. Two analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $7.00.

Precigen Price Performance

PGEN stock opened at $0.82 on Friday. The business’s 50 day simple moving average is $0.92 and its 200 day simple moving average is $1.24. Precigen has a 1-year low of $0.78 and a 1-year high of $1.93.

Institutional Trading of Precigen

A number of institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in shares of Precigen by 0.3% during the 1st quarter. Vanguard Group Inc. now owns 6,768,234 shares of the biotechnology company’s stock valued at $9,814,000 after acquiring an additional 19,875 shares during the period. Iridian Asset Management LLC CT lifted its position in shares of Precigen by 82.5% during the 3rd quarter. Iridian Asset Management LLC CT now owns 3,775,960 shares of the biotechnology company’s stock worth $3,576,000 after buying an additional 1,706,815 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Precigen by 4.8% during the 3rd quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company’s stock worth $3,075,000 after buying an additional 149,829 shares during the last quarter. State Street Corp lifted its position in shares of Precigen by 1.0% during the 3rd quarter. State Street Corp now owns 2,872,064 shares of the biotechnology company’s stock worth $2,720,000 after buying an additional 29,253 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Precigen by 11.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,222,850 shares of the biotechnology company’s stock worth $1,158,000 after buying an additional 127,467 shares during the last quarter. 33.51% of the stock is currently owned by institutional investors.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.